Affiance Financial’s TherapeuticsMD TXMD Stock Holding History

Affiance Financial’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-501	Closed	-$10K	–	134
2022 Q1	$10K	Hold	501	–	–	﹤0.01%	126
2021 Q4	$9K	Hold	501	–	–	﹤0.01%	144
2021 Q3	$19K	Hold	501	–	–	0.01%	139
2021 Q2	$30K	Hold	501	–	–	0.01%	137
2021 Q1	$34K	Hold	501	–	–	0.02%	132
2020 Q4	$30K	Hold	501	–	–	0.02%	121
2020 Q3	$40K	Hold	501	–	–	0.02%	116
2020 Q2	$31K	Hold	501	–	–	0.02%	112
2020 Q1	$27K	Hold	501	–	–	0.02%	104
2019 Q4	$61K	Hold	501	–	–	0.03%	111
2019 Q3	$91K	Hold	501	–	–	0.06%	94
2019 Q2	$65K	Hold	501	–	–	0.04%	92
2019 Q1	$122K	Hold	501	–	–	0.08%	91
2018 Q4	$95K	Hold	501	–	–	0.06%	92
2018 Q3	$164K	Hold	501	–	–	0.11%	88
2018 Q2	$156K	Buy	+501	New	+$153K	0.12%	88

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Affiance Financial's TXMD Position: Q2 2022 in Review

Affiance Financial sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 501 shares — an estimated $10K sold.

Affiance Financial first reported a position in TXMD in Q2 2018 and held it in 16 quarters. The position peaked at $164K in Q3 2018. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

Affiance Financial reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
Affiance Financial sold 501 TherapeuticsMD shares in Q2 2022, an estimated $10K.
Affiance Financial first reported a position in TherapeuticsMD in Q2 2018 and held it in 16 quarters.
Affiance Financial's TherapeuticsMD position peaked at $164K in Q3 2018.
53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Affiance Financial's 13F filing for Q2 2022, filed 14 Jul 2022.